CAJ | 학술논문

目的：探讨单用雷贝拉唑与法莫替丁联合莫沙必利治疗胃食管反流病的临床效果。方法选取2008年3月~2011年7月本院收治的胃食管反流病患者120例,随机分为治疗组和对照组各60例,治疗组应用雷贝拉唑进行治疗,1~4周口服雷贝拉唑20 mg,1次/d,5~12周改为隔日一次维持治疗；对照组应用法莫替丁进行治疗,1~4周用法莫替丁20 mg,2次/d,加莫沙必利5 mg,3次/d口服,5~12周维持用药则单用法莫替丁20 mg,2次/d。治疗第1、4、8、12周返院就诊,了解患者症状好转程度,第12周对原有食管炎者进行内镜检查以了解食管炎治愈情况。结果治疗组临床症状缓解率及食管炎治愈率明显高于对照组,差异有统计学意义(P<0.05)。结论与法莫替丁加莫沙必利相比,雷贝拉唑治疗胃食管反流病具有临床症状缓解快速、完全缓解率高的优势。
목적：탐토단용뢰패랍서여법막체정연합막사필리치료위식관반류병적림상효과。방법선취2008년3월~2011년7월본원수치적위식관반류병환자120례,수궤분위치료조화대조조각60례,치료조응용뢰패랍서진행치료,1~4주구복뢰패랍서20 mg,1차/d,5~12주개위격일일차유지치료；대조조응용법막체정진행치료,1~4주용법막체정20 mg,2차/d,가막사필리5 mg,3차/d구복,5~12주유지용약칙단용법막체정20 mg,2차/d。치료제1、4、8、12주반원취진,료해환자증상호전정도,제12주대원유식관염자진행내경검사이료해식관염치유정황。결과치료조림상증상완해솔급식관염치유솔명현고우대조조,차이유통계학의의(P<0.05)。결론여법막체정가막사필리상비,뢰패랍서치료위식관반류병구유림상증상완해쾌속、완전완해솔고적우세。
Objective To study the clinical efficiency of rabeprazole and famotidine united mosapride in treatment of gastroesophageal reflux disease. Methods 120 patients with gastroesophageal reflux disease treated in our hospital from March 2008 to July 2011 were selected and were randomly divided into treatment group and control group,60 cases in each group.The treatment group were taken with rabeprazole orally 20 mg per day from the first week to the fourth week,and taken with rabeprazole orally 20 mg every two days during the fifth week to the twelfth week.The control group were taken with famotidine orally 20 mg twice a day and taken with mosapride orally 5 mg three times a day from the first week to the fourth week,and taken with famotidine orally 20 mg twice a day during the fifth week to the twelfth week.All patients were required to see the doctor at the first,fourth,eighth and twelfth week.The progress of clin-ical symptoms were recorded.The patients with esophagitis were required gastroscopy at the twelfth week to observe the improvement of esophagitis. Results The relief rate of symptoms and the healing rate of esophagitis in the treatment group was higher than that in the control group respectively,the difference was significant (P<0.05). Conclusion Com-pared with famotidine united mosapride,rabeprazole for treatment of gastroesophageal reflux disease has the feature of more rapid symptom relief and higher relief rate.